<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Kidney transplantation in adults: BK polyomavirus-associated nephropathy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Kidney transplantation in adults: BK polyomavirus-associated nephropathy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Kidney transplantation in adults: BK polyomavirus-associated nephropathy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ajit P Limaye, MD, FACP, FIDSA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Daniel C Brennan, MD, FACP</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John Vella, MD, FACP, FRCP, FASN, FAST</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Emily A Blumberg, MD</a></dd><dt><span> </span>Deputy Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Albert Q Lam, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheila Bond, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 23, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H2221549963"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>BK polyomavirus (BKPyV) is a small DNA virus that establishes lifelong infection in the renal tubular and uroepithelial cells of most of the world's population. For the majority, infection is quiescent and benign. However, in immunocompromised patients, BKPyV can reactivate, and in some, lead to BKPyV-associated nephropathy (BKPyVAN).</p><p>Among kidney transplant recipients, BKPyV reactivation is common. Reactivation is frequently subclinical, although it may manifest with acute kidney injury (AKI), and is a risk factor for premature allograft loss. Thus, screening for reactivation is recommended for all kidney transplant recipients after transplantation. For those with clinically significant reactivation, reduction of immunosuppression is the cornerstone of management. There is no specific antiviral or immunomodulatory therapy sufficiently effective for routine use.</p><p>This topic will review the epidemiology, microbiology, pathogenesis, clinical manifestations, screening, diagnosis, and management of BKPyV infection in kidney transplant recipients. The general evaluation of kidney allograft dysfunction and other infections in solid organ transplant recipients are discussed separately:</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/1396.html" rel="external">"Infection in the solid organ transplant recipient"</a>.)</p><p></p><p class="headingAnchor" id="H3992270979"><span class="h1">EPIDEMIOLOGY</span></p><p class="headingAnchor" id="H1939559110"><span class="h2">Prevalence</span><span class="headingEndMark"> — </span>BK polyomavirus (BKPyV) is a ubiquitous virus with a worldwide seroprevalence of approximately 80 to 90 percent [<a href="#rid1">1-3</a>]. Primary infection is typically acquired during childhood, possibly via fecal-oral or respiratory transmission [<a href="#rid1">1,4,5</a>]. Following primary infection, the virus establishes lifelong infection in renal tubular and uroepithelial cells. For most individuals, both primary infection and persistent infection are clinically silent and not associated with any known adverse effects.</p><p>Among kidney transplant recipients, reactivation of latent infection or transmission of new infection via the donor kidney can lead to viruria (detection of intact virus or virus components in urine), viremia (typically by detection of viral DNA in blood), or allograft nephropathy (demonstration of virus or virus components in allograft tissue) [<a href="#rid6">6,7</a>]. Viral replication most commonly occurs during the first year after transplantation when cellular immunity is most suppressed. Viruria and viremia are detected in approximately 25 to 30 and 12 percent of kidney transplant recipients, respectively [<a href="#rid8">8,9</a>], and almost invariably precede the development of nephropathy in a stereotypical pattern of viruria, followed by viremia, followed by BKPyV-associated nephropathy (BKPyVAN).</p><p>Approximately 1 to 10 percent of kidney transplant recipients will develop BKPyVAN [<a href="#rid10">10-15</a>]. Historically, BKPyVAN was associated with graft loss rates that exceeded 50 percent [<a href="#rid16">16</a>]. However, with the implementation of standardized screening protocols, rates of short-term graft loss have fallen substantially [<a href="#rid8">8</a>].</p><p class="headingAnchor" id="H1997134964"><span class="h2">Risk factors for viral replication</span><span class="headingEndMark"> — </span>The intensity of immunosuppression (particularly suppression of cellular immunity) appears to be a dominant risk factor for BKPyV replication and disease. Consistent with this, replication rates are higher in the early posttransplant period and following treatment for allograft rejection when immunosuppression intensity is highest.</p><p>No specific immunosuppressive drug or regimen has been definitively associated with clinically significant BKPyV infection [<a href="#rid9">9,13,17-21</a>]. Several studies have suggested that certain drugs (particularly <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>) may be associated with an increased relative risk [<a href="#rid13">13,22,23</a>], while others (eg, mammalian [mechanistic] target of rapamycin [mTOR] inhibitors) may be associated with a lower relative risk [<a href="#rid24">24-27</a>]. However, BKPyV replication and BKPyVAN have occurred in patients receiving nearly all immunosuppressive drugs and their combinations [<a href="#rid9">9,12,14,17,28-34</a>].</p><p>Based on the observation that BKPyVAN occurs predominantly in the kidney allograft rather than in native kidneys, factors other than profound immunosuppression alone are likely important for disease development. Other important risk factors include high risk serostatus (ie, kidney transplant from a BKPyV-seropositive donor to a seronegative recipient) [<a href="#rid35">35,36</a>], impaired immune response to BKPyV [<a href="#rid36">36,37</a>], and donor BKPyV viruria prior to transplant [<a href="#rid38">38-40</a>]. The last two factors suggest that the donor is an important source of transmission and that viral serotype may play a role in pathogenesis [<a href="#rid38">38,41</a>].</p><p>Other risk factors associated with an increased risk of BKPyVAN or disease severity include older age [<a href="#rid23">23,42</a>], ureteral stent placement [<a href="#rid7">7</a>], ABO incompatibility [<a href="#rid43">43</a>], rejection or ischemia of the transplanted kidney [<a href="#rid44">44</a>], delayed graft function [<a href="#rid7">7</a>], HLA mismatch [<a href="#rid43">43,45-48</a>], specific HLA-C alleles [<a href="#rid41">41</a>], BKPyV polymorphisms [<a href="#rid49">49-51</a>], and transplantation from an HCV-positive donor [<a href="#rid52">52</a>].</p><p>By contrast, some factors have been associated with decreased risk of BKPyVAN. In one cohort of 407 living kidney donor-recipient pairs, recipient HLA-B51 positivity was associated with an approximate fivefold reduction in BKPyVAN (hazard ratio [HR] 0.18, 95% CI 0.04-0.73) [<a href="#rid53">53</a>]. Polycystic kidney disease has also been associated with a lower risk of BKPyVAN [<a href="#rid54">54</a>].</p><p>In one cohort study of over 20,000 mate kidney pairs, factors associated with BKPyVAN included use of an antibody-depleting agent for induction; age &lt;18 or ≥60 years; male sex; ≥4 HLA-A, -B, or -DR mismatches; and acute rejection [<a href="#rid55">55</a>]. Treatment for BKPyVAN was associated with an increased risk of allograft failure (HR 2.01, 95% CI 1.63-2.48). The leading cause of graft loss was BKPyVAN, occurring in 45 percent, followed by acute and chronic rejection in 25 and 12 percent, respectively.</p><p class="headingAnchor" id="H3513471421"><span class="h1">VIROLOGY</span><span class="headingEndMark"> — </span>BK polyomavirus (BKPyV) is a small (30 to 45 nm), icosahedral, nonenveloped, double-stranded, closed circular DNA virus [<a href="#rid5">5</a>]. The 5 kb genome encodes six viral proteins. There are two "early" nonstructural or enzymatic proteins, an agnoprotein, and three "late" proteins. The early proteins are the large tumor antigen, or "T antigen," and the small tumor antigen, or the "t antigen." The T antigen is responsible for cell immortalization and the establishment of latent infection. The agnogene, which transcribes the agnoprotein, appears to aid in the assembly of viral particles. The "late" genes encode three viral capsid proteins, VP-1, VP-2, and VP-3, which mediate cell entry and progeny virion assembly.</p><p>Noncoding control regions of the genome may be important in pathogenesis. Mutations in these regions can be progressively acquired during the course of an infection, leading to altered cell tropism, permissivity (ie, cell types that can support viral replication), and replication rates [<a href="#rid49">49-51</a>]. In kidney transplant recipients with clinically significant BKPyV replication, mutations in noncoding control regions have been associated with high BKPyV viral loads [<a href="#rid50">50</a>].</p><p>Virulence may also vary among serotypes, which differ genetically and in their cellular tropism [<a href="#rid5">5,56,57</a>]. Serotype I is the most prevalent and is responsible for most human disease. Neutralizing antibodies to one serotype do not appear to confer protection against others.</p><p class="headingAnchor" id="H1857001093"><span class="h1">PATHOGENESIS</span><span class="headingEndMark"> — </span>Insufficient cellular immune control is presumed to be an important part of BK polyomavirus (BKPyV)-associated nephropathy (BKPyVAN) pathogenesis [<a href="#rid18">18,58</a>]. After primary infection, which typically occurs in childhood, BKPyV maintains persistent infection in the renal and uroepithelium (transitional epithelium, renal tubular epithelium, and parietal epithelium of Bowman's capsule) of most individuals [<a href="#rid59">59-61</a>]. Control of this persistent infection is dependent on CD4+ and CD8+ T cell immunity [<a href="#rid58">58</a>]. When immune control is disrupted (as with immunosuppressive drugs), BKPyV can begin to actively replicate.</p><p>As viral replication persists, injury to the renal tubular epithelium results from direct viral replication and cell turnover. Subsequent inflammation and fibrosis lead to further injury and ultimately tubular atrophy, necrosis, and nephron loss [<a href="#rid62">62</a>]. The resultant inflammatory milieu may further promote viral replication and perpetuate injury [<a href="#rid48">48</a>]. Transcriptional analysis of kidney allograft tissue in BKPyVAN has demonstrated upregulation of multiple inflammatory pathways that overlap considerably with those seen in acute allograft rejection [<a href="#rid63">63,64</a>].</p><p>The development of alloimmunity and acute rejection (following reduction of immunosuppression in response to BKPyV replication) may further contribute to allograft dysfunction and potentially graft loss [<a href="#rid65">65</a>]. Preliminary data suggest that the kidney allograft inflammatory profile in BKPyVAN is similar to that seen in acute cellular rejection and involves both virus- and allograft-directed immune injury [<a href="#rid63">63,66</a>].</p><p class="headingAnchor" id="H2157727215"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>In kidney transplant recipients, BK polyomavirus (BKPyV) replication typically develops in stages: viruria followed by viremia and then, if viral replication persists, nephropathy can ensue (<a class="graphic graphic_figure graphicRef83389" href="/z/d/graphic/83389.html" rel="external">figure 1</a>).</p><p class="headingAnchor" id="H1271281179"><span class="h2">Viruria and viremia</span><span class="headingEndMark"> — </span>Viruria is the earliest manifestation of BKPyV infection in kidney transplant recipients, affecting approximately one-quarter to one-third of patients during the first year following transplantation (<a class="graphic graphic_figure graphicRef83389" href="/z/d/graphic/83389.html" rel="external">figure 1</a>) [<a href="#rid8">8,9</a>]. For most, viruria is asymptomatic, detected only by screening, and does not progress to viremia (see <a class="local">'Screening and diagnosis'</a> below). While viruria is a sensitive marker for progression to BKPyV-associated nephropathy (BKPyVAN), it is nonspecific [<a href="#rid67">67</a>]. Shedding of BKPyV in the urine (as detected by highly sensitive polymerase chain reaction [PCR] methods) is common among otherwise healthy older adult patients, pregnant women, and others with suppressed cellular immunity and is generally without clinical consequence [<a href="#rid42">42,68</a>]. Urine decoy cells (renal tubular or uroepithelial cells containing intranuclear viral inclusions), which typically represent higher-level viruria, may be present at this stage (<a class="graphic graphic_picture graphicRef101386" href="/z/d/graphic/101386.html" rel="external">picture 1</a> and <a class="graphic graphic_diagnosticimage graphicRef83969" href="/z/d/graphic/83969.html" rel="external">image 1</a>), but they do not have a significantly greater prognostic value for progression to viremia than detection of viruria by more sensitive methods such as PCR. (See <a class="local">'Urine quantitative PCR'</a> below and <a class="local">'Urine cytology'</a> below.)</p><p>Viremia may follow viruria in a few weeks and occurs most frequently in those with high urine viral loads and sustained viruria [<a href="#rid67">67,69,70</a>]. Viremia is detected in 10 to 30 percent of recipients in the first six months posttransplantation and in 5 to 10 percent of recipients thereafter. As with viruria, viremia is typically asymptomatic. However, viremia has a greater predictive value than viruria for progression to BKPyVAN [<a href="#rid8">8,70</a>]. Viremia is present in nearly all patients with BKPyVAN and has a positive predictive value of approximately 40 to 65 percent for the development of BKPyVAN [<a href="#rid67">67,71</a>]. Because BKPyVAN can quickly follow viremia (eg, within one to two weeks) and damage to the graft can be irreversible, viremia is a generally accepted indication to reduce immunosuppression in kidney transplant recipients. As with viruria, higher viral loads and sustained viremia have greater predictive value for concomitant or progression to biopsy-confirmed BKPyVAN. (See <a class="local">'Plasma quantitative PCR'</a> below and <a class="local">'Treatment'</a> below.)</p><p class="headingAnchor" id="H2277593979"><span class="h2">BKPyV-associated nephropathy (BKPyVAN)</span><span class="headingEndMark"> — </span>Asymptomatic viruria, viremia, and/or a slow progressive rise in serum creatinine are typically the only indicators of BKPyVAN. The incidence of BKPyVAN is highest in the first two to six months posttransplant. While the majority of cases occur in the first posttransplant year, BKPyVAN can occur years after transplantation [<a href="#rid72">72</a>]. The incidence of late BKPyVAN appears to be highest in patients with multi-organ transplants and is possibly related to the more intensive immunosuppressive regimens used for these patients.</p><p>Without resolution of infection, progressive kidney allograft dysfunction and graft loss can ensue over a period of months [<a href="#rid62">62</a>]. Within the allograft, early infection triggers interstitial inflammation, which then progresses to fibrosis and tubular injury. Accordingly, urinalysis may reveal pyuria, hematuria, and/or cellular casts consisting of renal tubular cells and inflammatory cells, or may be normal. (See <a class="local">'Histologic findings'</a> below.)</p><p>Reduction of immunosuppression is the primary means of restoring immunity and immune control of BKPyV replication. With this comes the risk of rejection, which can be difficult to distinguish clinically from progressive BKPyVAN [<a href="#rid73">73</a>]. (See <a class="local">'Distinguishing BKPyVAN from rejection'</a> below.)</p><p class="headingAnchor" id="H1577010788"><span class="h2">Other manifestations</span><span class="headingEndMark"> — </span>Hemorrhagic cystitis is a rare manifestation of BKPyV infection in kidney transplant recipients but is the most commonly reported manifestation of BKPyV infection among hematopoietic cell transplant recipients [<a href="#rid74">74,75</a>]. (See  <a class="medical medical_review" href="/z/d/html/1403.html" rel="external">"Overview of infections following hematopoietic cell transplantation", section on 'Hemorrhagic cystitis'</a>.)</p><p>There is a putative link between BKPyV and the development of genitourinary cancers, largely based upon viral-associated oncogenesis in animal models and the ability of the virus to transform cells in vitro [<a href="#rid76">76-78</a>]. However, a causal role for BKPyV and human malignancies has not been definitively established.</p><p class="headingAnchor" id="H3472079018"><span class="h1">SCREENING AND DIAGNOSIS</span></p><p class="headingAnchor" id="H4183756743"><span class="h2">Posttransplant screening</span><span class="headingEndMark"> — </span>We recommend routine screening for BK polyomavirus (BKPyV)-associated nephropathy (BKPyVAN) for all kidney transplant recipients in the early posttransplant period. Observational data suggest that screening and preemptive reduction in immunosuppression for patients with clinically significant BKPyV viremia prevent progression to BKPyVAN in the majority of patients [<a href="#rid22">22,79,80</a>]. The optimal screening strategy has not been determined, and approaches vary among transplant centers [<a href="#rid81">81-83</a>].</p><p>We screen patients with a quantitative plasma BKPyV polymerase chain reaction (PCR; ie, viral load) at the following time points:</p><p class="bulletIndent1"><span class="glyph">●</span>Monthly for the first six months following transplant, then every three months until two years posttransplant, and then annually until five years posttransplant</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Whenever kidney allograft dysfunction occurs or when an allograft biopsy is performed for allograft dysfunction</p><p></p><p>Clinical response varies and is dependent upon the degree of viremia, the patient's immunosuppressive regimen, and presence of allograft dysfunction. The threshold plasma BKPyV viral load that is considered positive or clinically significant varies according to the particular assay used. In general, levels &gt;1000 copies/mL are considered positive in most assays, and levels &gt;10,000 copies/mL correlate with biopsy-confirmed BKPyVAN. However, there is wide variability in the quantitation of BKPyV DNA across assays. (See <a class="local">'Plasma quantitative PCR'</a> below.)</p><p class="bulletIndent1"><span class="glyph">●</span>For patients with viremia (eg, viral loads &gt;1000 copies/mL) and normal allograft function, we typically reduce immunosuppression and monitor the viral load every two to four weeks thereafter to ensure that it is downtrending. (See <a class="local">'Reduction of immunosuppression'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>For patients with viremia and new-onset allograft dysfunction, we generally reduce immunosuppression and monitor viral loads every two to four weeks thereafter when the clinical picture suggests that BKPyVAN is the most likely cause. We consider a kidney allograft biopsy if the cause for kidney allograft dysfunction is uncertain or if kidney dysfunction and/or viremia fail to resolve despite reducing immunosuppression. (See  <a class="medical medical_review" href="/z/d/html/7301.html" rel="external">"Kidney transplantation in adults: Evaluation and diagnosis of acute kidney allograft dysfunction", section on 'Patients presenting with an elevated serum creatinine'</a>.)</p><p></p><p>Our approach is generally consistent with the Kidney Disease: Improving Global Outcomes (KDIGO) and American Society of Transplantation Infectious Diseases Community of Practice (AST-IDCOP) guidelines [<a href="#rid84">84,85</a>]. The AST-IDCOP takes a slightly more conservative approach to screening and recommends an initial monthly screening period of nine months rather than six months. Because approximately 85 percent of kidney transplant recipients who are going to become viremic develop BKPyV viremia within the first four months of transplantation, the utility of extending the screening period beyond six months is uncertain [<a href="#rid9">9,86</a>]. Other variations in practice include screening methods used and thresholds for reducing immunosuppression and obtaining a kidney allograft biopsy. As examples, some centers screen using a urine BKPyV PCR because of its high sensitivity and proceed to plasma PCR for those with viruria [<a href="#rid87">87</a>]; others may screen with urine cytology (for decoy cells) if PCR is not available. (See <a class="local">'Urine quantitative PCR'</a> below and <a class="local">'Urine cytology'</a> below.)</p><p>Several studies have evaluated the efficacy of a screening and preemptive strategy for BKPyVAN [<a href="#rid9">9,10,79,88,89</a>]. As examples:</p><p class="bulletIndent1"><span class="glyph">●</span>This approach was systematically evaluated in a trial of 200 kidney transplant recipients who were randomly assigned to receive either <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> in combination with an antimetabolite (<a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> or <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>) and low-dose <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> for maintenance immunosuppression [<a href="#rid9">9</a>]. All patients were monitored with PCR of blood and urine to detect early BKPyV viruria and viremia. At one year posttransplant, viruria (defined as &gt;2000 copies/mL of urine) and viremia (defined as &gt;2000 copies/mL of plasma) were noted in 35 and 12 percent, respectively. Upon detection of viremia, but not viruria, the antimetabolite (either mycophenolate or azathioprine) was discontinued; if viremia failed to clear within four weeks, the calcineurin inhibitor dose was reduced. This protocol resulted in resolution of viremia in 95 percent of patients without an increased risk of acute rejection, kidney dysfunction, or allograft loss. No patients developed biopsy-proven BKPyVAN. At five years, patient and graft survival were 91 and 84 percent, respectively, and there were no differences between those with BKPyV viruria detected in the first year posttransplant compared with those without BKPyV viruria [<a href="#rid17">17</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Similar findings were reported in a prospective study of 62 consecutive pediatric kidney transplant recipients who underwent screening for BKPyV with blood and urine BKPyV PCR at months 1, 3, 6, 9, 12, 18, 24, 36, and 48 after transplantation [<a href="#rid88">88</a>]. At a median of 24 months, 39 patients (63 percent) developed BKPyV viruria, and 13 (21 percent) developed BKPyV viremia. Patients with viremia were preemptively treated with reduction in immunosuppression (stepwise reduction in calcineurin inhibitor dose followed by stepwise reduction in <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> dose), which cleared viremia and prevented the development of BKPyVAN in all patients, without increasing the risk for rejection or graft dysfunction.</p><p></p><p class="headingAnchor" id="H125434470"><span class="h2">Testing methods</span></p><p class="headingAnchor" id="H2861682466"><span class="h3">Plasma quantitative PCR</span><span class="headingEndMark"> — </span>Quantification of plasma BKPyV DNA by real-time polymerase chain reaction (PCR) is the preferred screening test for BKPyVAN at most transplant centers (<a class="graphic graphic_table graphicRef122303" href="/z/d/graphic/122303.html" rel="external">table 1</a>) [<a href="#rid84">84,85</a>]. The detection of BKPyV viremia by plasma quantitative PCR is both highly sensitive (100 percent) and specific (88 percent) for the diagnosis of BKPyVAN and has a higher positive predictive value for BKPyVAN than the detection of viruria by urine quantitative PCR or urine cytology (50 to 60 percent versus 40 and 29 percent, respectively) [<a href="#rid10">10,29</a>]. The suggested frequency of screening after transplantation is described elsewhere in this topic. (See <a class="local">'Posttransplant screening'</a> above.)</p><p>In addition, following the initial detection of viremia, plasma PCR can be used to monitor the patient's response to therapy since a decrease in BKPyV viremia usually occurs soon after a reduction in immunosuppression and precedes a decrease in viruria by weeks to months [<a href="#rid9">9</a>]. Importantly, persistent high-grade viremia even in the absence of histologic evidence of BKPyVAN is associated with worse allograft function and risk of allograft loss [<a href="#rid62">62</a>].</p><p>There are no clearly established threshold levels for BKPyV viremia that predict BKPyVAN. However, most experts agree that a BKPyV viral load of ≥10,000 copies/mL, particularly when sustained for more than three weeks' duration, is highly suggestive of BKPyVAN ("presumptive" BKPyVAN) [<a href="#rid12">12,84</a>].</p><p>BKPyV DNA levels may vary substantially among assays [<a href="#rid90">90</a>], with variations of a magnitude of 1 to 2 log-fold in sequential weekly analyses in a commercially available quantitative PCR assay. This interassay variability complicates the interpretation of results and precludes the establishment of universally accepted thresholds for the management of BKPyV infection. To address this issue, the World Health Organization (WHO) introduced an international standard in 2016 to standardize viral load values among different laboratory assays when results are expressed as international units/mL [<a href="#rid91">91</a>]. Initial studies evaluating the utility of the WHO international standard have showed improved agreement in reporting across laboratories [<a href="#rid92">92,93</a>]. However, variability among laboratories still exists due to differences in DNA extraction techniques, amplicon size, and PCR primer design [<a href="#rid94">94</a>].</p><p class="headingAnchor" id="H3731397329"><span class="h3">Urine quantitative PCR</span><span class="headingEndMark"> — </span>We do not use quantitative PCR of the urine for BKPyV DNA to screen for BKPyVAN. Some transplant centers prefer to screen with urine polymerase chain reaction (PCR), given the high sensitivity and less invasive nature of this test, and proceed to plasma PCR for those with viruria (<a class="graphic graphic_table graphicRef122303" href="/z/d/graphic/122303.html" rel="external">table 1</a>) [<a href="#rid87">87</a>]. However, patients who are found to have viruria require confirmation with quantitative plasma PCR, since approximately one-half of patients with BKPyV viruria will not develop viremia or BKPyVAN. As such, the cost effectiveness of this approach has been questioned [<a href="#rid87">87</a>]. Furthermore, urine PCR for BKPyV DNA is not as useful as plasma PCR for monitoring the response to therapy, since changes in the urine viral load lag behind changes in the plasma viral load upon lowering immunosuppression. However, some studies suggest that the detection of high-grade viruria might be helpful to predict clinically significant viremia [<a href="#rid70">70,95</a>].</p><p class="headingAnchor" id="H1562753313"><span class="h3">Urine cytology</span><span class="headingEndMark"> — </span>Cytologic examination of the urine, which may reveal BKPyV-infected cells, is infrequently used to screen for BKPyVAN. Although the presence of characteristic cytopathologic changes in infected cells (which have been called decoy cells (<a class="graphic graphic_picture graphicRef101386" href="/z/d/graphic/101386.html" rel="external">picture 1</a>) due to their resemblance to renal carcinoma cells) is strongly suggestive of BKPyV infection [<a href="#rid10">10,96</a>], urine cytology is less sensitive and specific for the diagnosis of BKPyVAN compared with plasma quantitative PCR (<a class="graphic graphic_table graphicRef122303" href="/z/d/graphic/122303.html" rel="external">table 1</a>) [<a href="#rid10">10,29</a>]. In addition, the diagnostic utility of urine cytology is further limited by interobserver variability and the qualitative, rather than quantitative, nature of this test.</p><p></p><p class="headingAnchor" id="H2183160179"><span class="h3">Kidney allograft biopsy</span><span class="headingEndMark"> — </span>Kidney allograft biopsy is the gold standard for diagnosing BKPyVAN, assessing its severity, and evaluating for concomitant processes. However, because biopsy is invasive and sampling error can occur, a presumptive diagnosis is often made based upon the presence of significant viremia (plasma BKPyV viral load ≥10,000 copies/mL). (See <a class="local">'Plasma quantitative PCR'</a> above.)</p><p>A definitive diagnosis of BKPyVAN requires the following findings on kidney biopsy [<a href="#rid12">12,97,98</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Characteristic cytopathic changes. (See <a class="local">'Histologic findings'</a> below.)</p><p></p><p class="bulletIndent1"><strong>plus</strong></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Positive immunohistochemistry tests using antibodies directed specifically against BKPyV or against the cross-reacting SV40 large T antigen. Positive SV40 staining is useful as it is associated with a specificity of almost 100 percent for polyomavirus nephropathy (PVN), although it does not distinguish between BKPyV- and JC virus (JCV)-associated cases.</p><p></p><p>Because of the focal nature of early BKPyVAN, the diagnosis may be missed on one-third of biopsies. As a result, at least two biopsy cores, preferably including medulla, should be examined [<a href="#rid97">97,99,100</a>]. Medullary tissue should be included because BKPyV is more likely to be present in the medulla. If the initial biopsy does not confirm BKPyVAN, a repeat biopsy should be considered.</p><p class="headingAnchor" id="H1797876967"><span class="h4">Histologic findings</span><span class="headingEndMark"> — </span>BKPyVAN is associated with characteristic histologic findings on kidney biopsy. Since viral cytopathic changes can also can be observed with cytomegalovirus (CMV), adenovirus, and herpes simplex virus (HSV) infections, the morphologic changes may not be pathognomonic. They include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Intranuclear basophilic viral inclusions without a surrounding halo [<a href="#rid11">11,59,101,102</a>]. CMV has cytoplasmic inclusions, as noted above, and HSV has both intranuclear and cytoplasmic inclusions.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Anisonucleosis, hyperchromasia, and chromatin clumping of infected cells [<a href="#rid11">11,59,102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Interstitial mononuclear or polymorphonuclear cell infiltrates in the areas of tubular damage [<a href="#rid11">11,59,102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tubular injury, which is characterized by tubular cell apoptosis, cell drop out, desquamation, and flattened epithelial lining [<a href="#rid11">11,59,102</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Tubulitis, which is manifested by lymphocyte permeation of the tubular basement membrane. When extensive, it is difficult to differentiate BKPyVAN from allograft rejection [<a href="#rid11">11,59,101,102</a>]. (See <a class="local">'Distinguishing BKPyVAN from rejection'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>With electron microscopy, intranuclear viral inclusions (with a diameter size of 30 to 50 nm) and tubular damage characterized by tubular cell necrosis, prominent lysosomal inclusions, and luminal protein and cellular casts [<a href="#rid11">11,59,101,102</a>].</p><p></p><p>In 2017, the Banff Working Group on Polyomavirus Nephropathy established a classification system that defined three histologic classes of definitive (biopsy-proven) BKPyVAN on the basis of two morphologic variables: intrarenal polyomavirus replication/load levels (pvl) and Banff interstitial fibrosis (ci) scores [<a href="#rid103">103</a>]. The pvl score is based upon the extent of virally induced tubular changes. A tubule with intranuclear viral inclusion bodies (type 1 or 2) and/or a positive immunohistochemical reaction for SV40 large T antigen in one or more cells per tubular cross-section is considered "a positive tubule." The overall percentage of positive tubular cross-sections is estimated in the entire biopsy sample (ie, all available cores and all tubules/ducts in the cortex and medulla) and three levels of pvl are defined: pvl 1 = &lt;1 percent, pvl 2 = 1 to 10 percent, pvl 3 = &gt;10 percent positive tubules/ducts. The three histologic classes of PVN are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>PVN class 1 – pvl 1, ci ≤1</p><p class="bulletIndent1"><span class="glyph">●</span>PVN class 2 – pvl 1, ci ≥2 <strong>or </strong>pvl 2, any ci score <strong>or </strong>pvl 3, ci ≤1</p><p class="bulletIndent1"><span class="glyph">●</span>PVN class 3 – pvl 3, ci ≥2</p><p></p><p>In BKPyVAN classes 1 to 3, interstitial inflammation and tubulitis can vary from Banff scores ti 0 to ti 3/t0 to t3. BKPyVAN class 1 often lacks a significant inflammatory reaction. BKPyVAN and rejection (acute, chronic, cell mediated, and/or antibody mediated) can occur concomitantly. BKPyVAN classes are recorded in the context of the Banff classification scheme and established guidelines for Banff lesion scoring that should be recorded in parallel. To establish or exclude a diagnosis of definitive BKPyVAN, two biopsy cores including portions of medulla in at least one of the two cores are required.</p><p>In a retrospective analysis of 178 patients with biopsy-proven BKPyVAN, the Banff classification system was shown to correlate with clinical outcomes [<a href="#rid103">103</a>]. Twenty-five, 63, and 12 percent of patients were categorized as PVN class 1, 2, and 3, respectively. At 24 months after the initial diagnostic kidney allograft biopsy, the median increase in serum creatinine was 0.4 mg/dL, 1.0 mg/dL, and 4.8 mg/dL for patients with PVN class 1, 2, and 3, respectively. Graft failure occurred in 16, 31, and 50 percent of patients with PVN class 1, 2, and 3, respectively. Further validation of the Banff classification system has been reported [<a href="#rid104">104</a>]; however, this classification system has not been shown to directly correlate with clinical outcomes across all studies [<a href="#rid105">105</a>].</p><p>Two studies examined the longitudinal histologic evolution of BKPyVAN in sequential allograft biopsies and made several important observations [<a href="#rid62">62,106</a>]. SV40 T antigen-negative interstitial inflammation preceded a histologic diagnosis of BKPyVAN in up to 23 percent of cases with BKPyV viremia and was also present in cases of resolving BKPyVAN, suggesting that the SV40 T antigen stain may be falsely negative due to sampling error and/or limited staining sensitivity. Persistent high-level viremia was the most significant risk factor for destructive chronic infection and eventual allograft loss, but no single clinical or pathologic feature could predict the clinical course of BKPyVAN in an individual patient. A high proportion of cases eventually evolved to interstitial fibrosis and tubular atrophy, and graft failure was associated both with BKPyV and rejection resulting from attempts to treat BKPyVAN, highlighting the importance of prevention over treatment strategies.</p><p class="headingAnchor" id="H549960860"><span class="h4">Distinguishing BKPyVAN from rejection</span><span class="headingEndMark"> — </span>Allograft rejection may closely resemble BKPyVAN on kidney biopsy [<a href="#rid63">63,101</a>]. Distinguishing BKPyVAN from allograft rejection is important since treatment for presumed rejection with increased immunosuppression (without concomitant reduction in maintenance immunosuppression) may result in allograft loss if BKPyVAN is present.</p><p>BKPyVAN is generally distinguished from rejection by the presence of BKPyV inclusions and immunohistologic or in situ hybridization evidence of virally infected cells, which are usually tubular epithelial cells, rather than podocytes or endothelial cells [<a href="#rid11">11</a>]. It is important to correlate the histologic findings with PCR evidence of viremia. (See <a class="local">'Plasma quantitative PCR'</a> above.)</p><p>A separate issue is identifying coexisting lesions of BKPyVAN and acute rejection [<a href="#rid11">11,107,108</a>]. Whether BKPyVAN and T cell-mediated, antibody-mediated, or mixed rejection can exist concomitantly is controversial. Establishing a diagnosis of concomitant T cell-mediated rejection in a biopsy that has BKPyVAN is difficult since both the histologic features and transcriptional profiles of these two disorders are similar [<a href="#rid63">63,101</a>]. In general, the presence of extensive tubulitis in areas remote from the viral cytopathic changes suggests that acute rejection is present, in addition to BKPyVAN. The combined presence of endarteritis, fibrinoid vascular necrosis, glomerulitis, and C4d deposits along peritubular capillaries is conclusive evidence of concurrent rejection, although some patients with BKPyVAN without concurrent rejection may have C4d deposits in the tubular basement membrane [<a href="#rid12">12,109</a>]. (See <a class="local">'Concurrent BKPyVAN and acute rejection'</a> below.)</p><p>Among some patients, it may only be possible to distinguish the effects of BKPyV viral infection from those of rejection by empirically altering the immunosuppressive regimen and observing the clinical response. (See <a class="local">'Concurrent BKPyVAN and acute rejection'</a> below.)</p><p class="headingAnchor" id="H3568891128"><span class="h3">Other diagnostic methods</span><span class="headingEndMark"> — </span>Negative-staining electron microscopy of the urine of patients with BKPyVAN often reveals the presence of cast-like, three-dimensional polyomavirus aggregates, termed Haufen (<a class="graphic graphic_picture graphicRef122576" href="/z/d/graphic/122576.html" rel="external">picture 2</a>) [<a href="#rid110">110-112</a>]. Haufen form in injured tubules with BKPyV replication and a high intratubular uromodulin concentration and are excreted into the urine similar to other urinary casts. In one cohort study of &gt;300 kidney transplant recipients, the detection of Haufen in voided urine had a sensitivity, specificity, negative predictive value, and positive predictive value for biopsy-proven BKPyVAN of greater than 95 percent [<a href="#rid110">110</a>], suggesting that this may be a noninvasive way to diagnose BKPyVAN. However, the urinary Haufen test requires electron microscopy. Thus, it is not a widely used screening test, but it may be used in certain clinical scenarios, such as in pediatric patients or when a kidney allograft biopsy cannot be safely performed.</p><p class="headingAnchor" id="H3045936490"><span class="h1">TREATMENT</span></p><p class="headingAnchor" id="H2288618654"><span class="h2">Overview of treatment</span><span class="headingEndMark"> — </span>Since there are no specific antiviral therapies for BK polyomavirus (BKPyV)-associated nephropathy (BKPyVAN), the cornerstone of management is to decrease immunosuppressive medications [<a href="#rid12">12,84,85</a>]. In general, this approach applies to both the prevention of BKPyVAN in patients with BKPyV viremia detected by routine screening (see <a class="local">'Posttransplant screening'</a> above) and the treatment of patients with established BKPyVAN. The optimal approach to reducing immunosuppression has not been defined; protocols vary among transplant centers and are often individualized. (See <a class="local">'Reduction of immunosuppression'</a> below.)</p><p>The initial approach of decreasing immunosuppressive medications is effective in most patients. For patients who have progressive allograft dysfunction, despite a maximal decrease in immunosuppressive therapy for a period of several weeks to months, we may try agents that may have antiviral and/or immunomodulatory activity, such as intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG). However, the efficacy of this approach has not been proven. We do not use <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>, <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a>, or quinolone antibiotics. (See <a class="local">'Adjunctive therapies'</a> below.)</p><p class="headingAnchor" id="H2766178837"><span class="h2">Reduction of immunosuppression</span><span class="headingEndMark"> — </span>We recommend reducing maintenance immunosuppression for most kidney transplant recipients with detectable BKPyV viremia or biopsy-proven BKPyVAN. The goals of reducing immunosuppression are to restore immunity against BKPyV without triggering rejection. Approaches to reducing immunosuppression vary among transplant centers, and there are no randomized controlled trials that directly compare different protocols.</p><p>Patients should be closely monitored while immunosuppression is being decreased since additional interventions are based upon the clinical and virologic response. The complete resolution of viremia may take several months. Prior to reducing immunosuppression, we obtain a plasma BKPyV quantitative polymerase chain reaction (PCR) (see <a class="local">'Plasma quantitative PCR'</a> above) and subsequently monitor the plasma quantitative PCR every one to two weeks until BKPyV DNA is undetectable for two consecutive tests obtained at least one week apart. In addition, we monitor the serum creatinine level weekly. If the serum creatinine level increases by ≥25 percent from baseline at any time while immunosuppression is being reduced, the patient should be evaluated for the possibility of acute rejection. (See <a class="local">'Acute rejection after reducing immunosuppression'</a> below.)</p><p>In patients who do <strong>not</strong> have concurrent acute rejection (see <a class="local">'Concurrent BKPyVAN and acute rejection'</a> below), our approach to reducing immunosuppression is as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are on a triple immunosuppression therapy consisting of a calcineurin inhibitor (<a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> or <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>), an antimetabolite (<a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil/sodium or <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>), and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, we initially reduce the dose of the antimetabolite by 50 percent. If the BKPyV viral load does not decrease within two to four weeks, we completely discontinue the antimetabolite. If there is still no decrease in viral load after another two weeks, we decrease the dose of the calcineurin inhibitor by 25 to 50 percent, targeting a whole blood tacrolimus trough level of 4 to 6 ng/mL or a whole blood cyclosporine trough level of 60 to 100 ng/mL.</p><p></p><p class="bulletIndent1">An alternative approach that is used by others is to first decrease the dose of the calcineurin inhibitor by 25 to 50 percent in one or two steps, followed by reducing the antimetabolite by 50 percent, followed by discontinuing the antimetabolite [<a href="#rid84">84</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In patients who are on a glucocorticoid-free maintenance regimen with a calcineurin inhibitor and an antimetabolite without <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, a similar approach as described above for patients on triple immunosuppression therapy may be used. However, transplant centers may feel less inclined to use monotherapy with either a calcineurin inhibitor or antimetabolite. An alternative approach is to reduce both the calcineurin inhibitor and the <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a>, which allows both the targeting of two pathways and lower total immunosuppression.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Following resolution of BKPyV viremia or biopsy-proven BKPyVAN, the decision to increase the level of maintenance immunosuppression should be individualized, taking into consideration the risk of acute rejection as well as the risk for recurrent BKPyV. Evidence from one randomized trial with long-term follow-up suggests that patients with BKPyV viremia can be safely maintained on reduced immunosuppression for at least 10 years without an increase in acute rejection or graft loss [<a href="#rid9">9,17,113</a>]. </p><p></p><p>Although the cornerstone of management is to decrease immunosuppressive medications, the effectiveness of this strategy has not been evaluated systematically in randomized trials. In one meta-analysis of observational data from 40 studies, graft loss rates were similar when comparing reduction in immunosuppression alone versus reduction of immunosuppression plus either <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> or <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> [<a href="#rid114">114</a>]. Similar findings have been reported in subsequent cohort studies [<a href="#rid79">79,115,116</a>].</p><p class="headingAnchor" id="H2426830016"><span class="h2">Adjunctive therapies</span><span class="headingEndMark"> — </span>Several agents have been shown to have in vitro anti-BKPyV activity. However, we do <strong>not</strong> routinely use any of these agents for the treatment of BKPyV infection, given that the efficacy of these agents has not been established and use of these therapies has not been clearly shown to be superior to reduction in immunosuppression alone [<a href="#rid114">114</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Intravenous </strong><strong>immune globulin</strong> – Commercially available <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> preparations contain BKPyV-neutralizing antibodies against all major genotypes [<a href="#rid117">117</a>]. We do not routinely administer IVIG for the treatment of BKPyVAN. However, the adjunctive use of IVIG may be considered in patients with established BKPyVAN who do not respond to a reduction in immunosuppression and who also have severe hypogammaglobulinemia (ie, immunoglobulin G [IgG] &lt;400 mg/dL). (See  <a class="medical medical_review" href="/z/d/html/4431.html" rel="external">"Overview of intravenous immune globulin (IVIG) therapy"</a>.)</p><p></p><p class="bulletIndent1">If used, <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> is administered at a dose of 300 mg/kg every three weeks in conjunction with a reduction in immunosuppression. We typically administer intravenous hydration with normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> (10 to 20 mL/kg) prior to starting the infusion to mitigate the risk of acute kidney injury (AKI). We repeat 21-day trough IgG levels after three months of therapy with the goal of maintaining an IgG level &gt;400 mg/dL. (See <a class="local">'Reduction of immunosuppression'</a> above and  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects", section on 'Acute kidney injury'</a> and  <a class="medical medical_review" href="/z/d/html/3944.html" rel="external">"Intravenous immune globulin: Adverse effects", section on 'Strategies for reducing adverse events'</a>.)</p><p></p><p class="bulletIndent1">Limited data are available concerning the efficacy of <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">IVIG</a> in patients with BKPyVAN. Some observational studies have reported clearance of BKPyV viremia following IVIG therapy [<a href="#rid118">118-122</a>]. However, the findings of these studies are difficult to evaluate, since other antiviral interventions were administered concurrently.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Leflunomide</strong> – <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">Leflunomide</a> is a prodrug; its active metabolite, A77 1726, has both immunosuppressive and antiviral activity [<a href="#rid123">123,124</a>]. We do <strong>not</strong> use leflunomide for the treatment of BKPyV infection given its uncertain efficacy, long half-life, the potential for hematologic toxicity and hepatotoxicity, the wide interpatient A77 1726 level variability in metabolism, and the inability to easily monitor A77 1726 levels.</p><p></p><p class="bulletIndent1">Studies on the efficacy of <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> have yielded mixed results. In an initial case series, there was improvement or stabilization in 23 of 26 patients with BKPyVAN after discontinuing <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, targeting <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a> levels to 4 to 6 ng/mL, maintaining <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> at 5 to 10 mg/day, and replacing mycophenolate with leflunomide with target levels of 50 to 100 mcg/mL. However, other observational studies have not found a benefit to treatment with leflunomide [<a href="#rid123">123,125,126</a>].</p><p></p><p class="bulletIndent1">Additionally, in a phase II randomized trial, an investigational agent derived from an active metabolite of <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a> (FK778) provided no clinically significant benefit compared with the reduction of immunosuppressive agents [<a href="#rid127">127</a>]. In this trial, 30 patients were administered FK778 in addition to having <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> discontinued completely. In the control group of 16 patients, mycophenolate dose was decreased by 40 to 60 percent. In both groups, calcineurin inhibitors were decreased by 40 to 60 percent. At six months, there was a slightly greater reduction of viremia but no improvement in kidney function in the FK778 group compared with control.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cidofovir</strong> – <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">Cidofovir</a> is a nucleotide analog of cytosine that is active against various DNA viruses and is approved for both HIV-associated cytomegalovirus (CMV) retinitis and the topical treatment of genital warts. Cidofovir has modest in vitro activity against polyomaviruses [<a href="#rid128">128</a>]. It should <strong>only</strong> be considered for treatment of BKPyVAN when other interventions have failed; it has been used anecdotally, in combination with antinucleoside therapy, for HIV-infected patients with progressive multifocal leukoencephalopathy (PML) resulting from polyomavirus infection.</p><p></p><p class="bulletIndent1">Only a few uncontrolled studies have evaluated the use of <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> in BKPyVAN [<a href="#rid129">129-131</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In a retrospective study of 21 patients with BKPyVAN, eight were administered weekly adjuvant low-dose <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> plus a reduction in immunosuppressive therapy, while 13 were treated with reduced immunosuppressive therapy alone [<a href="#rid131">131</a>]. At a median period of 25 months, all allografts of those administered cidofovir survived. By comparison, 9 of 13 allografts of those not given cidofovir were lost at a median period of eight months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In one report of four patients, including two children, <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a> was effective in all four [<a href="#rid129">129</a>].</p><p></p><p class="bulletIndent1">However, a small randomized trial of kidney transplant recipients with BKPyVAN found that treatment with <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a>, compared with placebo, had minimal effect on the BKPyV viral load in plasma or urine [<a href="#rid132">132</a>].</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">Cidofovir</a> is potentially highly nephrotoxic, resulting in proteinuria and kidney failure in 20 percent of patients [<a href="#rid128">128,133</a>]. In addition, this agent has caused at least one case of subacute interstitial nephritis, which led to end-stage kidney disease (ESKD) [<a href="#rid128">128</a>]. It is also associated with other adverse effects.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Quinolone antibiotics</strong> – We do <strong>not </strong>use quinolone antibiotics as an adjunctive therapy to treat BKPyV infection. Although quinolone antibiotics were initially reported to have anti-BKPyV activity [<a href="#rid134">134-138</a>], two randomized trials showed no benefit of <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> given either prophylactically immediately following transplantation or as treatment for active BKPyV viremia [<a href="#rid139">139,140</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>One trial included 154 allograft recipients transplanted between 2011 and 2013 [<a href="#rid140">140</a>]. Recipients were randomly assigned to receive three months of either <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> (500 mg per day) or placebo beginning within five days after transplantation. At a mean follow-up of 46 weeks, there was no difference between the levofloxacin and placebo groups in the incidence of BKPyV viruria, viremia, peak viral load, rejection, or patient or allograft survival. There was an increased incidence of infections caused by resistant bacterial isolates that are usually sensitive to quinolones in the levofloxacin versus the placebo group (58 versus 33 percent, respectively [risk ratio 1.75, 95% CI 1.01-2.98]).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>A placebo-controlled, randomized trial including 39 transplant recipients with BKPyV viremia showed no benefit of <a class="drug drug_general" data-topicid="9554" href="/z/d/drug information/9554.html" rel="external">levofloxacin</a> (given at a dose of 500 mg daily for 30 days) over placebo for either reduction of viral load at one, three, or six months, or allograft function [<a href="#rid139">139</a>]. However, participating centers used different immunosuppressive protocols, which may have affected the rate of BKPyV viremia, and different assays for BKPyV viremia [<a href="#rid141">141</a>]. Despite these limitations, this study suggests that one month of levofloxacin at this dose does not clear BKPyV viremia after transplantation.</p><p></p><p class="headingAnchor" id="H852992153"><span class="h2">Experimental therapies</span><span class="headingEndMark"> — </span>Based upon the important role of cellular and humoral immune mechanisms in control of BKPyV infection, and the absence of other proven treatments, immune-based therapies are being actively assessed in human clinical trials:</p><p class="bulletIndent1"><span class="glyph">●</span>Virus-specific T cells (VSTs) against BKPyV are being assessed for safety, tolerability, and antiviral effect in an ongoing multicenter trial of kidney transplant recipients with BKPyV viremia, based upon encouraging preliminary results of VSTs for BKPyV-associated hemorrhagic cystitis or nephropathy in hematopoietic cell transplant recipients (ClinicalTrials.gov identifier: NCT04605484).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>BKPyV-specific monoclonal antibodies are being assessed for safety, tolerability, and antiviral effect in an ongoing multicenter trial of kidney transplant recipients with BKPyV viremia (ClinicalTrials.gov identifier: NCT04294472).</p><p></p><p class="headingAnchor" id="H3171359953"><span class="h2">Special considerations</span></p><p class="headingAnchor" id="H3601656690"><span class="h3">Concurrent BKPyVAN and acute rejection</span><span class="headingEndMark"> — </span>The coexistence of BKPyVAN and acute rejection in a kidney allograft biopsy remains controversial [<a href="#rid22">22,84,142,143</a>]. (See <a class="local">'Distinguishing BKPyVAN from rejection'</a> above.)</p><p>There are no data to guide the optimal management of patients with concurrent BKPyVAN and acute rejection. Some experts advocate for treating the acute rejection first (eg, with pulse glucocorticoids) and then subsequently reducing immunosuppression as a second step once the patient has had a clinical response to antirejection treatment (ie, a decrease in serum creatinine level) [<a href="#rid84">84</a>]. By contrast, other experts avoid augmented immunosuppression and favor a reduction in maintenance immunosuppression alone [<a href="#rid9">9,79,115,144,145</a>]. If immunosuppression is augmented, more frequent monitoring of BKPyV viremia may be warranted. (See  <a class="medical medical_review" href="/z/d/html/7326.html" rel="external">"Kidney transplantation in adults: Prevention and treatment of antibody-mediated rejection", section on 'Approach to initial therapy'</a> and  <a class="medical medical_review" href="/z/d/html/7358.html" rel="external">"Kidney transplantation in adults: Treatment of acute T cell-mediated (cellular) rejection", section on 'Approach based on histologic severity'</a>.)</p><p class="headingAnchor" id="H470881214"><span class="h3">Acute rejection after reducing immunosuppression</span><span class="headingEndMark"> — </span>Acute rejection can occur in 8 to 12 percent of kidney transplant recipients with BKPyV viremia or established BKPyVAN following a reduction in immunosuppression [<a href="#rid17">17,79,116</a>]. Acute rejection should be suspected in patients whose serum creatinine levels increase after immunosuppression has been decreased. Obtaining a kidney allograft biopsy in this setting may be helpful to establish the diagnosis of rejection. However, as discussed above, the histologic findings of acute rejection can be difficult to distinguish from those of BKPyVAN. (See <a class="local">'Distinguishing BKPyVAN from rejection'</a> above.)</p><p>The optimal approach to managing patients who develop acute rejection after reducing immunosuppression is not well defined and frequently varies from center to center. In general, we avoid augmenting immunosuppression in such patients if they have biopsy-confirmed BKPyVAN and maintain immunosuppression at the same reduced level as it was when the patient developed rejection.</p><p class="headingAnchor" id="H1295248748"><span class="h1">KIDNEY RETRANSPLANTATION</span><span class="headingEndMark"> — </span>Retransplantation in patients with graft failure due to BK polyomavirus (BKPyV)-associated nephropathy (BKPyVAN) is a reasonable option and has been successfully performed [<a href="#rid146">146-150</a>]. In general, the absence of BKPyV replication should be confirmed prior to retransplantation [<a href="#rid12">12</a>], although successful preemptive, living, related kidney transplants during active BKPyVAN with viremia have been reported [<a href="#rid151">151</a>]. We typically wait until BKPyV viremia has completely resolved before proceeding with retransplantation. Because BKPyVAN appears to be donor derived and cytotoxicity mediated, this usually necessitates continued close screening following retransplantation. Some centers recommend avoiding intense immunosuppression and graft injury. We do not routinely perform nephrectomy of the failed allograft or of the native kidneys, which may serve as a reservoir and a source of reinfection, as there are no high-quality data to support this approach.</p><p>Limited information exists concerning the outcome of a kidney transplant among patients who lost their first allograft because of BKPyVAN [<a href="#rid150">150,152,153</a>]; however, available data suggest that retransplantation in these patients is generally associated with good graft outcomes. In the largest study to examine this issue, outcomes were compared between 341 patients who were retransplanted for first graft failure resulting from BKPyVAN and 13,260 patients who were retransplanted for first graft failure resulting from other causes [<a href="#rid150">150</a>]. Five-year, death-censored graft survival rates were 91 percent for the BKPyVAN group and 84 percent for the non-BKPyVAN group. There was no significant difference in the rates of acute rejection or patient survival at one year between the two groups.</p><p class="headingAnchor" id="H3423045894"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117423.html" rel="external">"Society guideline links: BK virus infection in kidney transplant recipients"</a>.)</p><p class="headingAnchor" id="H2254765203"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Important background</strong> – BK polyomavirus (BKPyV) is a small DNA virus that establishes lifelong persistent infection in the renal tubular and uroepithelial cells of most of the world's population. For the majority, this infection is quiescent and benign. However, in immunocompromised patients, BKPyV can reactivate, leading to clinically significant disease. (See <a class="local">'Prevalence'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors for viral replication</strong> – In kidney transplant recipients, BKPyV-associated disease typically occurs in the early posttransplant period when immunosuppression is most intense. Other factors associated with BKPyV disease include high-risk serostatus (ie, transplant from a BKPyV-seropositive donor to a seronegative recipient), impaired donor immune response to BKPyV, and donor BKPyV viruria prior to transplant. (See <a class="local">'Risk factors for viral replication'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – BKPyV replication typically progress through three stages. Asymptomatic viruria occurs in approximately one-quarter to one-third of patients during the first posttransplant year. Viremia follows viruria in approximately one-half of patients. In a subset of viremic patients, viral replication progresses leading to damage to renal tubular epithelium and BKPyV-associated nephropathy (BKPyVAN). Like viruria and viremia, BKPyVAN is typically asymptomatic, and a rise in serum creatinine may be the sole presenting sign. Without control of viral replication, allograft loss can ensue within a period of months. (See <a class="local">'Clinical manifestations'</a> above and <a class="local">'Pathogenesis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening and diagnosis</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We recommend routine screening for BKPyVAN for all kidney transplant recipients in the early posttransplant period. Screening and preemptive reduction in immunosuppression for patients with clinically significant BKPyV viremia prevent progression to BKPyVAN in the majority of patients. The optimal screening strategy has not been determined, and approaches vary among transplant centers. We screen patients with a quantitative plasma BKPyV polymerase chain reaction (PCR; ie, viral load) at the following time points (see <a class="local">'Posttransplant screening'</a> above):</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Monthly for the first six months following transplant, then every three months until two years posttransplant, and then annually until five years posttransplant</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Whenever kidney allograft dysfunction occurs or when an allograft biopsy is performed for allograft dysfunction</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Clinical response varies and is dependent upon the degree of viremia, the patient's immunosuppressive regimen, and presence of allograft dysfunction:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with viremia (eg, viral loads &gt;1000 copies/mL) and normal allograft function, we typically reduce immunosuppression and monitor the viral load every two to four weeks thereafter to ensure that it is downtrending.</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with viremia and new-onset allograft dysfunction, we generally reduce immunosuppression and monitor viral loads every two to four weeks thereafter, when the clinical picture suggests that BKPyVAN is the most likely cause. We consider a kidney allograft biopsy if the cause for kidney allograft dysfunction is uncertain or if kidney dysfunction and/or viremia fail to resolve despite reducing immunosuppression. (See <a class="local">'Posttransplant screening'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Kidney allograft biopsy is the gold standard for diagnosing BKPyVAN, assessing its severity, and evaluating for concomitant processes. However, because biopsy is invasive and sampling error can occur, a presumptive diagnosis is often made based upon the presence of significant viremia (plasma BKPyV viral load ≥10,000 copies/mL). (See <a class="local">'Kidney allograft biopsy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>In kidney transplant recipients with detectable BKPyV viremia or biopsy-proven BKPyVAN, we recommend reducing maintenance immunosuppression. The optimal approach to reducing immunosuppression has not been defined; protocols vary among transplant centers and are often individualized. (See <a class="local">'Overview of treatment'</a> above and <a class="local">'Reduction of immunosuppression'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Several agents have been shown to have in vitro anti-BKPyV activity, including intravenous <a class="drug drug_general" data-topicid="16471" href="/z/d/drug information/16471.html" rel="external">immune globulin</a> (IVIG), <a class="drug drug_general" data-topicid="10097" href="/z/d/drug information/10097.html" rel="external">leflunomide</a>, <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">cidofovir</a>, and quinolone antibiotics. However, we do <strong>not</strong> routinely use any of these agents for the treatment of BKPyV infection, given that the efficacy of these agents has not been established and use of these therapies has not been clearly shown to be superior to reduction in immunosuppression alone. (See <a class="local">'Adjunctive therapies'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Knowles WA, Pipkin P, Andrews N, et al. Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. J Med Virol 2003; 71:115.</a></li><li><a class="nounderline abstract_t">Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog 2009; 5:e1000363.</a></li><li><a class="nounderline abstract_t">Antonsson A, Green AC, Mallitt KA, et al. Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians. J Gen Virol 2010; 91:1849.</a></li><li><a class="nounderline abstract_t">Pahari A, Rees L. BK virus-associated renal problems--clinical implications. Pediatr Nephrol 2003; 18:743.</a></li><li><a class="nounderline abstract_t">Helle F, Brochot E, Handala L, et al. Biology of the BKPyV: An Update. Viruses 2017; 9.</a></li><li><a class="nounderline abstract_t">Gupta M, Miller F, Nord EP, Wadhwa NK. Delayed renal allograft dysfunction and cystitis associated with human polyomavirus (BK) infection in a renal transplant recipient: a case report and review of literature. Clin Nephrol 2003; 60:405.</a></li><li><a class="nounderline abstract_t">Chong S, Antoni M, Macdonald A, et al. BK virus: Current understanding of pathogenicity and clinical disease in transplantation. Rev Med Virol 2019; 29:e2044.</a></li><li><a class="nounderline abstract_t">Manzano Sánchez D, Jimeno García L, Manzano Sánchez D, et al. Renal Function Impairment in Kidney Transplantation: Importance of Early BK Virus Detection. Transplant Proc 2019; 51:350.</a></li><li><a class="nounderline abstract_t">Brennan DC, Agha I, Bohl DL, et al. Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction. Am J Transplant 2005; 5:582.</a></li><li><a class="nounderline abstract_t">Hirsch HH, Knowles W, Dickenmann M, et al. Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients. N Engl J Med 2002; 347:488.</a></li><li><a class="nounderline abstract_t">Nickeleit V, Hirsch HH, Zeiler M, et al. BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game. Nephrol Dial Transplant 2000; 15:324.</a></li><li><a class="nounderline abstract_t">Hirsch HH, Brennan DC, Drachenberg CB, et al. Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations. Transplantation 2005; 79:1277.</a></li><li><a class="nounderline abstract_t">Dharnidharka VR, Cherikh WS, Abbott KC. An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States. Transplantation 2009; 87:1019.</a></li><li><a class="nounderline abstract_t">Schold JD, Rehman S, Kayle LK, et al. Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States. Transpl Int 2009; 22:626.</a></li><li><a class="nounderline abstract_t">van Aalderen MC, Heutinck KM, Huisman C, ten Berge IJ. BK virus infection in transplant recipients: clinical manifestations, treatment options and the immune response. Neth J Med 2012; 70:172.</a></li><li><a class="nounderline abstract_t">Vasudev B, Hariharan S, Hussain SA, et al. BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients. Kidney Int 2005; 68:1834.</a></li><li><a class="nounderline abstract_t">Hardinger KL, Koch MJ, Bohl DJ, et al. BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results. Am J Transplant 2010; 10:407.</a></li><li><a class="nounderline abstract_t">Schachtner T, Stein M, Babel N, Reinke P. The Loss of BKV-specific Immunity From Pretransplantation to Posttransplantation Identifies Kidney Transplant Recipients at Increased Risk of BKV Replication. Am J Transplant 2015; 15:2159.</a></li><li><a class="nounderline abstract_t">Schachtner T, Stein M, Sefrin A, et al. Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV replication after renal transplantation. Transpl Int 2014; 27:290.</a></li><li><a class="nounderline abstract_t">Schaenman JM, Korin Y, Sidwell T, et al. Increased Frequency of BK Virus-Specific Polyfunctional CD8+ T Cells Predict Successful Control of BK Viremia After Kidney Transplantation. Transplantation 2017; 101:1479.</a></li><li><a class="nounderline abstract_t">Cioni M, Leboeuf C, Comoli P, et al. Characterization of Immunodominant BK Polyomavirus 9mer Epitope T Cell Responses. Am J Transplant 2016; 16:1193.</a></li><li><a class="nounderline abstract_t">Hirsch HH, Vincenti F, Friman S, et al. Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study. Am J Transplant 2013; 13:136.</a></li><li><a class="nounderline abstract_t">Demey B, Tinez C, François C, et al. Risk factors for BK virus viremia and nephropathy after kidney transplantation: A systematic review. J Clin Virol 2018; 109:6.</a></li><li><a class="nounderline abstract_t">Moscarelli L, Caroti L, Antognoli G, et al. Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience. Clin Transplant 2013; 27:546.</a></li><li><a class="nounderline abstract_t">Tohme FA, Kalil RS, Thomas CP. Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients. Transpl Infect Dis 2015; 17:66.</a></li><li><a class="nounderline abstract_t">Wojciechowski D, Chandran S, Webber A, et al. Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients. Transplant Proc 2017; 49:1773.</a></li><li><a class="nounderline abstract_t">Mallat SG, Tanios BY, Itani HS, et al. CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials. Clin J Am Soc Nephrol 2017; 12:1321.</a></li><li><a class="nounderline abstract_t">Gardner SD, MacKenzie EF, Smith C, Porter AA. Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients. J Clin Pathol 1984; 37:578.</a></li><li><a class="nounderline abstract_t">Nickeleit V, Klimkait T, Binet IF, et al. Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy. N Engl J Med 2000; 342:1309.</a></li><li><a class="nounderline abstract_t">Bressollette-Bodin C, Coste-Burel M, Hourmant M, et al. A prospective longitudinal study of BK virus infection in 104 renal transplant recipients. Am J Transplant 2005; 5:1926.</a></li><li><a class="nounderline abstract_t">Fink JC, Wiland AM, Rochussen JR, et al. The increased incidence of BK polyomavirus in renal transplant recipients treated with Prograf. Transplantation 2000; 69:S385.</a></li><li><a class="nounderline abstract_t">Mengel M, Marwedel M, Radermacher J, et al. Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs. Nephrol Dial Transplant 2003; 18:1190.</a></li><li><a class="nounderline abstract_t">Dadhania D, Snopkowski C, Ding R, et al. Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication. Transplantation 2008; 86:521.</a></li><li><a class="nounderline abstract_t">van Doesum WB, Gard L, Bemelman FJ, et al. Incidence and outcome of BK polyomavirus infection in a multicenter randomized controlled trial with renal transplant patients receiving cyclosporine-, mycophenolate sodium-, or everolimus-based low-dose immunosuppressive therapy. Transpl Infect Dis 2017; 19.</a></li><li><a class="nounderline abstract_t">Sood P, Senanayake S, Sujeet K, et al. Donor and recipient BKV-specific IgG antibody and posttransplantation BKV infection: a prospective single-center study. Transplantation 2013; 95:896.</a></li><li><a class="nounderline abstract_t">Abend JR, Changala M, Sathe A, et al. Correlation of BK Virus Neutralizing Serostatus With the Incidence of BK Viremia in Kidney Transplant Recipients. Transplantation 2017; 101:1495.</a></li><li><a class="nounderline abstract_t">Wunderink HF, van der Meijden E, van der Blij-de Brouwer CS, et al. Pretransplantation Donor-Recipient Pair Seroreactivity Against BK Polyomavirus Predicts Viremia and Nephropathy After Kidney Transplantation. Am J Transplant 2017; 17:161.</a></li><li><a class="nounderline abstract_t">Schwarz A, Linnenweber-Held S, Heim A, et al. Viral Origin, Clinical Course, and Renal Outcomes in Patients With BK Virus Infection After Living-Donor Renal Transplantation. Transplantation 2016; 100:844.</a></li><li><a class="nounderline abstract_t">Verghese PS, Schmeling DO, Knight JA, et al. The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study. Transplantation 2015; 99:602.</a></li><li><a class="nounderline abstract_t">Tan SK, Huang C, Sahoo MK, et al. Impact of Pretransplant Donor BK Viruria in Kidney Transplant Recipients. J Infect Dis 2019; 220:370.</a></li><li><a class="nounderline abstract_t">Bohl DL, Storch GA, Ryschkewitsch C, et al. Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia. Am J Transplant 2005; 5:2213.</a></li><li><a class="nounderline abstract_t">Zhong S, Zheng HY, Suzuki M, et al. Age-related urinary excretion of BK polyomavirus by nonimmunocompromised individuals. J Clin Microbiol 2007; 45:193.</a></li><li><a class="nounderline abstract_t">Sharif A, Alachkar N, Bagnasco S, et al. Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients. Clin J Am Soc Nephrol 2012; 7:1320.</a></li><li><a class="nounderline abstract_t">Bohl DL, Brennan DC. BK virus nephropathy and kidney transplantation. Clin J Am Soc Nephrol 2007; 2 Suppl 1:S36.</a></li><li><a class="nounderline abstract_t">Awadalla Y, Randhawa P, Ruppert K, et al. HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients. Am J Transplant 2004; 4:1691.</a></li><li><a class="nounderline abstract_t">Masutani K, Ninomiya T, Randhawa P. HLA-A2, HLA-B44 and HLA-DR15 are associated with lower risk of BK viremia. Nephrol Dial Transplant 2013; 28:3119.</a></li><li><a class="nounderline abstract_t">Bentall A, Neil D, Sharif A, Ball S. ABO-incompatible kidney transplantation is a novel risk factor for BK nephropathy. Transplantation 2015; 99:e8.</a></li><li><a class="nounderline abstract_t">Babel N, Volk HD, Reinke P. BK polyomavirus infection and nephropathy: the virus-immune system interplay. Nat Rev Nephrol 2011; 7:399.</a></li><li><a class="nounderline abstract_t">Funk GA, Steiger J, Hirsch HH. Rapid dynamics of polyomavirus type BK in renal transplant recipients. J Infect Dis 2006; 193:80.</a></li><li><a class="nounderline abstract_t">Gosert R, Rinaldo CH, Funk GA, et al. Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology. J Exp Med 2008; 205:841.</a></li><li><a class="nounderline abstract_t">Olsen GH, Andresen PA, Hilmarsen HT, et al. Genetic variability in BK Virus regulatory regions in urine and kidney biopsies from renal-transplant patients. J Med Virol 2006; 78:384.</a></li><li><a class="nounderline abstract_t">Molnar MZ, Potluri VS, Schaubel DE, et al. Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation. Am J Transplant 2022; 22:599.</a></li><li><a class="nounderline abstract_t">Wunderink HF, Haasnoot GW, de Brouwer CS, et al. Reduced Risk of BK Polyomavirus Infection in HLA-B51-positive Kidney Transplant Recipients. Transplantation 2019; 103:604.</a></li><li><a class="nounderline abstract_t">Plafkin C, Singh T, Astor BC, et al. Kidney transplant recipients with polycystic kidney disease have a lower risk of post-transplant BK infection than those with end-stage renal disease due to other causes. Transpl Infect Dis 2018; 20:e12974.</a></li><li><a class="nounderline abstract_t">Thangaraju S, Gill J, Wright A, et al. Risk Factors for BK Polyoma Virus Treatment and Association of Treatment With Kidney Transplant Failure: Insights From a Paired Kidney Analysis. Transplantation 2016; 100:854.</a></li><li><a class="nounderline abstract_t">Pastrana DV, Ray U, Magaldi TG, et al. BK polyomavirus genotypes represent distinct serotypes with distinct entry tropism. J Virol 2013; 87:10105.</a></li><li><a class="nounderline abstract_t">Baksh FK, Finkelstein SD, Swalsky PA, et al. Molecular genotyping of BK and JC viruses in human polyomavirus-associated interstitial nephritis after renal transplantation. Am J Kidney Dis 2001; 38:354.</a></li><li><a class="nounderline abstract_t">Ambalathingal GR, Francis RS, Smyth MJ, et al. BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies. Clin Microbiol Rev 2017; 30:503.</a></li><li><a class="nounderline abstract_t">Drachenberg CB, Beskow CO, Cangro CB, et al. Human polyoma virus in renal allograft biopsies: morphological findings and correlation with urine cytology. Hum Pathol 1999; 30:970.</a></li><li><a class="nounderline abstract_t">Shah KV. Human polyomavirus BKV and renal disease. Nephrol Dial Transplant 2000; 15:754.</a></li><li><a class="nounderline abstract_t">Chesters PM, Heritage J, McCance DJ. Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues. J Infect Dis 1983; 147:676.</a></li><li><a class="nounderline abstract_t">Nankivell BJ, Renthawa J, Sharma RN, et al. BK Virus Nephropathy: Histological Evolution by Sequential Pathology. Am J Transplant 2017; 17:2065.</a></li><li><a class="nounderline abstract_t">Mannon RB, Hoffmann SC, Kampen RL, et al. Molecular evaluation of BK polyomavirus nephropathy. Am J Transplant 2005; 5:2883.</a></li><li><a class="nounderline abstract_t">Adam BA, Kikic Z, Wagner S, et al. Intragraft gene expression in native kidney BK virus nephropathy versus T cell-mediated rejection: Prospects for molecular diagnosis and risk prediction. Am J Transplant 2020; 20:3486.</a></li><li><a class="nounderline abstract_t">Sawinski D, Forde KA, Trofe-Clark J, et al. Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies. J Am Soc Nephrol 2015; 26:966.</a></li><li><a class="nounderline abstract_t">Zeng G, Huang Y, Huang Y, et al. Antigen-Specificity of T Cell Infiltrates in Biopsies With T Cell-Mediated Rejection and BK Polyomavirus Viremia: Analysis by Next Generation Sequencing. Am J Transplant 2016; 16:3131.</a></li><li><a class="nounderline abstract_t">Elfadawy N, Yamada M, Sarabu N. Management of BK Polyomavirus Infection in Kidney and Kidney-Pancreas Transplant Recipients: A Review Article. Infect Dis Clin North Am 2018; 32:599.</a></li><li><a class="nounderline abstract_t">McClure GB, Gardner JS, Williams JT, et al. Dynamics of pregnancy-associated polyomavirus urinary excretion: a prospective longitudinal study. J Med Virol 2012; 84:1312.</a></li><li><a class="nounderline abstract_t">Brochot E, Descamps V, Handala L, et al. BK polyomavirus in the urine for follow-up of kidney transplant recipients. Clin Microbiol Infect 2019; 25:112.e1.</a></li><li><a class="nounderline abstract_t">Madden K, Janitell C, Sower D, Yang S. Prediction of BK viremia by urine viral load in renal transplant patients: An analysis of BK viral load results in paired urine and plasma samples. Transpl Infect Dis 2018; 20:e12952.</a></li><li><a class="nounderline abstract_t">Pinto GG, Poloni JA, Rotta LN, et al. Screening for BK virus nephropathy in kidney transplant recipients: comparison of diagnostic tests. J Bras Nefrol 2016; 38:356.</a></li><li><a class="nounderline abstract_t">Imlay H, Whitaker K, Fisher CE, Limaye AP. Clinical characteristics and outcomes of late-onset BK virus nephropathy in kidney and kidney-pancreas transplant recipients. Transpl Infect Dis 2018; 20:e12928.</a></li><li><a class="nounderline abstract_t">Baek CH, Kim H, Yu H, et al. Risk Factors of Acute Rejection in Patients with BK Nephropathy After Reduction of Immunosuppression. Ann Transplant 2018; 23:704.</a></li><li><a class="nounderline abstract_t">Kamal M, Govil A, Anand M, et al. Severe BK polyomavirus-induced hemorrhagic cystitis in a kidney transplant recipient with the absence of renal allograft involvement. Transpl Infect Dis 2018; 20.</a></li><li><a class="nounderline abstract_t">Kerbauy LN, Kerbauy MN, Bautzer V, et al. Severe hemorrhagic cystitis caused by the BK polyomavirus is associated with decreased survival post-allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2019; 21:e13101.</a></li><li><a class="nounderline abstract_t">Abend JR, Jiang M, Imperiale MJ. BK virus and human cancer: innocent until proven guilty. Semin Cancer Biol 2009; 19:252.</a></li><li><a class="nounderline abstract_t">Geetha D, Tong BC, Racusen L, et al. Bladder carcinoma in a transplant recipient: evidence to implicate the BK human polyomavirus as a causal transforming agent. Transplantation 2002; 73:1933.</a></li><li><a class="nounderline abstract_t">Gupta G, Kuppachi S, Kalil RS, et al. Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States. Am J Transplant 2018; 18:245.</a></li><li><a class="nounderline abstract_t">Schaub S, Hirsch HH, Dickenmann M, et al. Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy. Am J Transplant 2010; 10:2615.</a></li><li><a class="nounderline abstract_t">Petrov R, Elbahloul O, Gallichio MH, et al. Monthly screening for polyoma virus eliminates BK nephropathy and preserves renal function. Surg Infect (Larchmt) 2009; 10:85.</a></li><li><a class="nounderline abstract_t">Gabardi S, Pavlakis M, Tan C, et al. New England BK consortium: Regional survey of BK screening and management protocols in comparison to published consensus guidelines. Transpl Infect Dis 2018; 20:e12985.</a></li><li><a class="nounderline abstract_t">Hodowanec AC, Simon DM. BK virus screening and management practices among US renal transplant programs: a survey. Transpl Int 2015; 28:1339.</a></li><li><a class="nounderline abstract_t">Pape L, Tönshoff B, Hirsch HH, Members of the Working Group ‘Transplantation’ of the European Society for Paediatric Nephrology. Perception, diagnosis and management of BK polyomavirus replication and disease in paediatric kidney transplant recipients in Europe. Nephrol Dial Transplant 2016; 31:842.</a></li><li><a class="nounderline abstract_t">Hirsch HH, Randhawa PS, AST Infectious Diseases Community of Practice. BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13528.</a></li><li><a class="nounderline abstract_t">Kidney Disease: Improving Global Outcomes (KDIGO) Transplant Work Group. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009; 9 Suppl 3:S1.</a></li><li><a class="nounderline abstract_t">Randhawa P, Brennan DC. BK virus infection in transplant recipients: an overview and update. Am J Transplant 2006; 6:2000.</a></li><li><a class="nounderline abstract_t">Laskin BL, Goebel J. Cost-efficient screening for BK virus in pediatric kidney transplantation: a single-center experience and review of the literature. Pediatr Transplant 2010; 14:589.</a></li><li><a class="nounderline abstract_t">Ginevri F, Azzi A, Hirsch HH, et al. Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients. Am J Transplant 2007; 7:2727.</a></li><li><a class="nounderline abstract_t">Knight RJ, Gaber LW, Patel SJ, et al. Screening for BK viremia reduces but does not eliminate the risk of BK nephropathy: a single-center retrospective analysis. Transplantation 2013; 95:949.</a></li><li><a class="nounderline abstract_t">Hoffman NG, Cook L, Atienza EE, et al. Marked variability of BK virus load measurement using quantitative real-time PCR among commonly used assays. J Clin Microbiol 2008; 46:2671.</a></li><li class="breakAll">World Health Organization. 2016. First World Health Organization international standard for BK virus DNA. NIBSC code, 14/212. World Health Organization, Geneva, Switzerland.</li><li><a class="nounderline abstract_t">Govind S, Hockley J, Morris C, et al. The development and establishment of the 1st WHO BKV International Standard for nucleic acid based techniques. Biologicals 2019; 60:75.</a></li><li><a class="nounderline abstract_t">Tan SK, Milligan S, Sahoo MK, et al. Calibration of BK Virus Nucleic Acid Amplification Testing to the 1st WHO International Standard for BK Virus. J Clin Microbiol 2017; 55:923.</a></li><li><a class="nounderline abstract_t">Bateman AC, Greninger AL, Atienza EE, et al. Quantification of BK Virus Standards by Quantitative Real-Time PCR and Droplet Digital PCR Is Confounded by Multiple Virus Populations in the WHO BKV International Standard. Clin Chem 2017; 63:761.</a></li><li><a class="nounderline abstract_t">Chon WJ, Aggarwal N, Kocherginsky M, et al. High-level viruria as a screening tool for BK virus nephropathy in renal transplant recipients. Kidney Res Clin Pract 2016; 35:176.</a></li><li><a class="nounderline abstract_t">Ramos E, Drachenberg CB, Papadimitriou JC, et al. Clinical course of polyoma virus nephropathy in 67 renal transplant patients. J Am Soc Nephrol 2002; 13:2145.</a></li><li><a class="nounderline abstract_t">Drachenberg CB, Papadimitriou JC. Polyomavirus-associated nephropathy: update in diagnosis. Transpl Infect Dis 2006; 8:68.</a></li><li><a class="nounderline abstract_t">Wiseman AC. Polyomavirus nephropathy: a current perspective and clinical considerations. Am J Kidney Dis 2009; 54:131.</a></li><li><a class="nounderline abstract_t">Drachenberg CB, Papadimitriou JC, Hirsch HH, et al. Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load. Am J Transplant 2004; 4:2082.</a></li><li><a class="nounderline abstract_t">The American Society of Transplantation Infectious Diseases Guidelines. Am J Transplant 2009; 9(Suppl 4):S92.</a></li><li><a class="nounderline abstract_t">Randhawa PS, Finkelstein S, Scantlebury V, et al. Human polyoma virus-associated interstitial nephritis in the allograft kidney. Transplantation 1999; 67:103.</a></li><li><a class="nounderline abstract_t">Howell DN, Smith SR, Butterly DW, et al. Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients. Transplantation 1999; 68:1279.</a></li><li><a class="nounderline abstract_t">Nickeleit V, Singh HK, Randhawa P, et al. The Banff Working Group Classification of Definitive Polyomavirus Nephropathy: Morphologic Definitions and Clinical Correlations. J Am Soc Nephrol 2018; 29:680.</a></li><li><a class="nounderline abstract_t">Nickeleit V, Singh HK, Dadhania D, et al. The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: A multicenter validation study in the modern era. Am J Transplant 2021; 21:669.</a></li><li><a class="nounderline abstract_t">Bouatou Y, Nguyen TQ, Roelofs JJTH, et al. A Multicenter Application of the 2018 Banff Classification for BK Polyomavirus-associated Nephropathy in Renal Transplantation. Transplantation 2019; 103:2692.</a></li><li><a class="nounderline abstract_t">Drachenberg CB, Papadimitriou JC, Chaudhry MR, et al. Histological Evolution of BK Virus-Associated Nephropathy: Importance of Integrating Clinical and Pathological Findings. Am J Transplant 2017; 17:2078.</a></li><li><a class="nounderline abstract_t">McGilvray ID, Lajoie G, Humar A, Cattral MS. Polyomavirus infection and acute vascular rejection in a kidney allograft: coincidence or mimicry? Am J Transplant 2003; 3:501.</a></li><li><a class="nounderline abstract_t">Atsumi H, Asaka M, Kimura S, et al. A case of second renal transplantation with acute antibody-mediated rejection complicated with BK virus nephropathy. Clin Transplant 2010; 24 Suppl 22:35.</a></li><li><a class="nounderline abstract_t">Batal I, Zainah H, Stockhausen S, et al. The significance of renal C4d staining in patients with BK viruria, viremia, and nephropathy. Mod Pathol 2009; 22:1468.</a></li><li><a class="nounderline abstract_t">Singh HK, Andreoni KA, Madden V, et al. Presence of urinary Haufen accurately predicts polyomavirus nephropathy. J Am Soc Nephrol 2009; 20:416.</a></li><li><a class="nounderline abstract_t">Singh HK, Reisner H, Derebail VK, et al. Polyomavirus nephropathy: quantitative urinary polyomavirus-Haufen testing accurately predicts the degree of intrarenal viral disease. Transplantation 2015; 99:609.</a></li><li><a class="nounderline abstract_t">Nickeleit V, Singh HK. Polyomaviruses and disease: is there more to know than viremia and viruria? Curr Opin Organ Transplant 2015; 20:348.</a></li><li><a class="nounderline abstract_t">Seifert ME, Gunasekaran M, Horwedel TA, et al. Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation. J Am Soc Nephrol 2017; 28:1314.</a></li><li><a class="nounderline abstract_t">Johnston O, Jaswal D, Gill JS, et al. Treatment of polyomavirus infection in kidney transplant recipients: a systematic review. Transplantation 2010; 89:1057.</a></li><li><a class="nounderline abstract_t">Sood P, Senanayake S, Sujeet K, et al. Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study. Transplantation 2012; 94:814.</a></li><li><a class="nounderline abstract_t">Bischof N, Hirsch HH, Wehmeier C, et al. Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation: long-term outcomes. Nephrol Dial Transplant 2019; 34:1240.</a></li><li><a class="nounderline abstract_t">Randhawa P, Pastrana DV, Zeng G, et al. Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK. Am J Transplant 2015; 15:1014.</a></li><li><a class="nounderline abstract_t">Sener A, House AA, Jevnikar AM, et al. Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients. Transplantation 2006; 81:117.</a></li><li><a class="nounderline abstract_t">Kable K, Davies CD, O'connell PJ, et al. Clearance of BK Virus Nephropathy by Combination Antiviral Therapy With Intravenous Immunoglobulin. Transplant Direct 2017; 3:e142.</a></li><li><a class="nounderline abstract_t">Sharma AP, Moussa M, Casier S, et al. Intravenous immunoglobulin as rescue therapy for BK virus nephropathy. Pediatr Transplant 2009; 13:123.</a></li><li><a class="nounderline abstract_t">Vu D, Shah T, Ansari J, et al. Efficacy of intravenous immunoglobulin in the treatment of persistent BK viremia and BK virus nephropathy in renal transplant recipients. Transplant Proc 2015; 47:394.</a></li><li><a class="nounderline abstract_t">Benotmane I, Solis M, Velay A, et al. Intravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV-associated nephropathy in kidney transplant recipients-Results from a proof-of-concept study. Am J Transplant 2021; 21:329.</a></li><li><a class="nounderline abstract_t">Josephson MA, Gillen D, Javaid B, et al. Treatment of renal allograft polyoma BK virus infection with leflunomide. Transplantation 2006; 81:704.</a></li><li><a class="nounderline abstract_t">Chong AS, Zeng H, Knight DA, et al. Concurrent antiviral and immunosuppressive activities of leflunomide in vivo. Am J Transplant 2006; 6:69.</a></li><li><a class="nounderline abstract_t">Krisl JC, Taber DJ, Pilch N, et al. Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection. Clin J Am Soc Nephrol 2012; 7:1003.</a></li><li><a class="nounderline abstract_t">Faguer S, Hirsch HH, Kamar N, et al. Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation. Transpl Int 2007; 20:962.</a></li><li><a class="nounderline abstract_t">Guasch A, Roy-Chaudhury P, Woodle ES, et al. Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy. Transplantation 2010; 90:891.</a></li><li><a class="nounderline abstract_t">Vandercam B, Moreau M, Goffin E, et al. Cidofovir-induced end-stage renal failure. Clin Infect Dis 1999; 29:948.</a></li><li><a class="nounderline abstract_t">Vats A, Shapiro R, Singh Randhawa P, et al. Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults. Transplantation 2003; 75:105.</a></li><li><a class="nounderline abstract_t">Keller LS, Peh CA, Nolan J, et al. BK transplant nephropathy successfully treated with cidofovir. Nephrol Dial Transplant 2003; 18:1013.</a></li><li><a class="nounderline abstract_t">Kuypers DR, Vandooren AK, Lerut E, et al. Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients. Am J Transplant 2005; 5:1997.</a></li><li class="breakAll">https://clinicaltrials.gov/ct2/show/results/NCT00138424?term=cidofovir&amp;cond=bk+virus&amp;rank=1 (Accessed on August 21, 2019).</li><li><a class="nounderline abstract_t">Bagnis C, Izzdine H, Deray G. [Renal tolerance of cidofovir]. Therapie 1999; 54:689.</a></li><li><a class="nounderline abstract_t">Josephson MA, Williams JW, Chandraker A, Randhawa PS. Polyomavirus-associated nephropathy: update on antiviral strategies. Transpl Infect Dis 2006; 8:95.</a></li><li><a class="nounderline abstract_t">Leung AY, Chan MT, Yuen KY, et al. Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation. Clin Infect Dis 2005; 40:528.</a></li><li><a class="nounderline abstract_t">Chang CY, Gangji A, Chorneyko K, Kapoor A. Urological manifestations of BK polyomavirus in renal transplant recipients. Can J Urol 2005; 12:2829.</a></li><li><a class="nounderline abstract_t">Ali SH, Chandraker A, DeCaprio JA. Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones. Antivir Ther 2007; 12:1.</a></li><li><a class="nounderline abstract_t">Gabardi S, Waikar SS, Martin S, et al. Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation. Clin J Am Soc Nephrol 2010; 5:1298.</a></li><li><a class="nounderline abstract_t">Lee BT, Gabardi S, Grafals M, et al. Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial. Clin J Am Soc Nephrol 2014; 9:583.</a></li><li><a class="nounderline abstract_t">Knoll GA, Humar A, Fergusson D, et al. Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial. JAMA 2014; 312:2106.</a></li><li><a class="nounderline abstract_t">Anwar S, Brennan DC. Treatment of BK viremia after renal transplantation: are fluoroquinolones a false dawn? Clin J Am Soc Nephrol 2014; 9:445.</a></li><li><a class="nounderline abstract_t">Kayler LK, Batal I, Mohanka R, et al. Antirejection treatment in kidney transplant patients with BK viruria. Transplantation 2008; 86:797.</a></li><li><a class="nounderline abstract_t">Kayler LK, Kiss L, Sharma V, et al. Acute renal allograft rejection: diagnostic significance of focal peritubular capillary C4d. Transplantation 2008; 85:813.</a></li><li><a class="nounderline abstract_t">Saad ER, Bresnahan BA, Cohen EP, et al. Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy. Transplantation 2008; 85:850.</a></li><li><a class="nounderline abstract_t">Steubl D, Baumann M, Schuster T, et al. Risk factors and interventional strategies for BK polyomavirus infection after renal transplantation. Scand J Urol Nephrol 2012; 46:466.</a></li><li><a class="nounderline abstract_t">Geetha D, Sozio SM, Ghanta M, et al. Results of repeat renal transplantation after graft loss from BK virus nephropathy. Transplantation 2011; 92:781.</a></li><li><a class="nounderline abstract_t">Huang J, Danovitch G, Pham PT, et al. Kidney retransplantation for BK virus nephropathy with active viremia without allograft nephrectomy. J Nephrol 2015; 28:773.</a></li><li><a class="nounderline abstract_t">Poduval RD, Meehan SM, Woodle ES, et al. Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis. Transplantation 2002; 73:1166.</a></li><li><a class="nounderline abstract_t">Ginevri F, Pastorino N, de Santis R, et al. Retransplantation after kidney graft loss due to polyoma BK virus nephropathy: successful outcome without original allograft nephrectomy. Am J Kidney Dis 2003; 42:821.</a></li><li><a class="nounderline abstract_t">Leeaphorn N, Thongprayoon C, Chon WJ, et al. Outcomes of kidney retransplantation after graft loss as a result of BK virus nephropathy in the era of newer immunosuppressant agents. Am J Transplant 2020; 20:1334.</a></li><li><a class="nounderline abstract_t">Womer KL, Meier-Kriesche HU, Patton PR, et al. Preemptive retransplantation for BK virus nephropathy: successful outcome despite active viremia. Am J Transplant 2006; 6:209.</a></li><li><a class="nounderline abstract_t">Ramos E, Vincenti F, Lu WX, et al. Retransplantation in patients with graft loss caused by polyoma virus nephropathy. Transplantation 2004; 77:131.</a></li><li><a class="nounderline abstract_t">Dharnidharka VR, Cherikh WS, Neff R, et al. Retransplantation after BK virus nephropathy in prior kidney transplant: an OPTN database analysis. Am J Transplant 2010; 10:1312.</a></li></ol></div><div id="topicVersionRevision">Topic 7338 Version 37.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12858417" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19325891" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Seroepidemiology of human polyomaviruses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20219899" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Prevalence and stability of antibodies to the BK and JC polyomaviruses: a long-term longitudinal study of Australians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12802640" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : BK virus-associated renal problems--clinical implications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29099746" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Biology of the BKPyV: An Update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14690258" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Delayed renal allograft dysfunction and cystitis associated with human polyomavirus (BK) infection in a renal transplant recipient: a case report and review of literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30958614" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : BK virus: Current understanding of pathogenicity and clinical disease in transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30879539" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Renal Function Impairment in Kidney Transplantation: Importance of Early BK Virus Detection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15707414" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Incidence of BK with tacrolimus versus cyclosporine and impact of preemptive immunosuppression reduction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12181403" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prospective study of polyomavirus type BK replication and nephropathy in renal-transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10692517" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : BK-virus nephropathy in renal transplants-tubular necrosis, MHC-class II expression and rejection in a puzzling game.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15912088" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Polyomavirus-associated nephropathy in renal transplantation: interdisciplinary analyses and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19352121" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : An OPTN analysis of national registry data on treatment of BK virus allograft nephropathy in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19207187" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Treatment for BK virus: incidence, risk factors and outcomes for kidney transplant recipients in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22641625" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : BK virus infection in transplant recipients: clinical manifestations, treatment options and the immune response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16164661" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : BK virus nephritis: risk factors, timing, and outcome in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20055811" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : BK-virus and the impact of pre-emptive immunosuppression reduction: 5-year results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25808077" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : The Loss of BKV-specific Immunity From Pretransplantation to Posttransplantation Identifies Kidney Transplant Recipients at Increased Risk of BKV Replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24279642" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV replication after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27391197" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Increased Frequency of BK Virus-Specific Polyfunctional CD8+ T Cells Predict Successful Control of BK Viremia After Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26663765" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Characterization of Immunodominant BK Polyomavirus 9mer Epitope T Cell Responses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23137180" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Polyomavirus BK replication in de novo kidney transplant patients receiving tacrolimus or cyclosporine: a prospective, randomized, multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30343190" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Risk factors for BK virus viremia and nephropathy after kidney transplantation: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23758330" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Everolimus leads to a lower risk of BKV viremia than mycophenolic acid in de novo renal transplantation patients: a single-center experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25582442" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Conversion to a sirolimus-based regimen is associated with lower incidence of BK viremia in low-risk kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28923623" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Mycophenolate Mofetil Withdrawal With Conversion to Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28576905" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : CMV and BKPyV Infections in Renal Transplant Recipients Receiving an mTOR Inhibitor-Based Regimen Versus a CNI-Based Regimen: A Systematic Review and Meta-Analysis of Randomized, Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6327777" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Prospective study of the human polyomaviruses BK and JC and cytomegalovirus in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10793163" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Testing for polyomavirus type BK DNA in plasma to identify renal-allograft recipients with viral nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996241" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : A prospective longitudinal study of BK virus infection in 104 renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : The increased incidence of BK polyomavirus in renal transplant recipients treated with Prograf</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12748354" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Incidence of polyomavirus-nephropathy in renal allografts: influence of modern immunosuppressive drugs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18724220" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Epidemiology of BK virus in renal allograft recipients: independent risk factors for BK virus replication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28258601" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Incidence and outcome of BK polyomavirus infection in a multicenter randomized controlled trial with renal transplant patients receiving cyclosporine-, mycophenolate sodium-, or everolimus-based low-dose immunosuppressive therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23511214" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Donor and recipient BKV-specific IgG antibody and posttransplantation BKV infection: a prospective single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27854236" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Correlation of BK Virus Neutralizing Serostatus With the Incidence of BK Viremia in Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27251361" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Pretransplantation Donor-Recipient Pair Seroreactivity Against BK Polyomavirus Predicts Viremia and Nephropathy After Kidney Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26720302" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Viral Origin, Clinical Course, and Renal Outcomes in Patients With BK Virus Infection After Living-Donor Renal Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25148381" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : The impact of donor viral replication at transplant on recipient infections posttransplant: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30869132" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Impact of Pretransplant Donor BK Viruria in Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16095500" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Donor origin of BK virus in renal transplantation and role of HLA C7 in susceptibility to sustained BK viremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17093017" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Age-related urinary excretion of BK polyomavirus by nonimmunocompromised individuals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22626962" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17699509" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : BK virus nephropathy and kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15367226" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : HLA mismatching increases the risk of BK virus nephropathy in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24084328" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : HLA-A2, HLA-B44 and HLA-DR15 are associated with lower risk of BK viremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25651124" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : ABO-incompatible kidney transplantation is a novel risk factor for BK nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21610680" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : BK polyomavirus infection and nephropathy: the virus-immune system interplay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16323135" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Rapid dynamics of polyomavirus type BK in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18347101" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Polyomavirus BK with rearranged noncoding control region emerge in vivo in renal transplant patients and increase viral replication and cytopathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16419108" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Genetic variability in BK Virus regulatory regions in urine and kidney biopsies from renal-transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34613666" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Association of donor hepatitis C virus infection status and risk of BK polyomavirus viremia after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30048396" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Reduced Risk of BK Polyomavirus Infection in HLA-B51-positive Kidney Transplant Recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30102820" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Kidney transplant recipients with polycystic kidney disease have a lower risk of post-transplant BK infection than those with end-stage renal disease due to other causes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27003098" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Risk Factors for BK Polyoma Virus Treatment and Association of Treatment With Kidney Transplant Failure: Insights From a Paired Kidney Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23843634" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : BK polyomavirus genotypes represent distinct serotypes with distinct entry tropism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11479162" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Molecular genotyping of BK and JC viruses in human polyomavirus-associated interstitial nephritis after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28298471" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : BK Polyomavirus: Clinical Aspects, Immune Regulation, and Emerging Therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10452511" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Human polyoma virus in renal allograft biopsies: morphological findings and correlation with urine cytology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10831621" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Human polyomavirus BKV and renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6302172" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Persistence of DNA sequences of BK virus and JC virus in normal human tissues and in diseased tissues.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28371308" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : BK Virus Nephropathy: Histological Evolution by Sequential Pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16303001" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Molecular evaluation of BK polyomavirus nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32372431" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Intragraft gene expression in native kidney BK virus nephropathy versus T cell-mediated rejection: Prospects for molecular diagnosis and risk prediction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25255921" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Persistent BK viremia does not increase intermediate-term graft loss but is associated with de novo donor-specific antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27273900" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Antigen-Specificity of T Cell Infiltrates in Biopsies With T Cell-Mediated Rejection and BK Polyomavirus Viremia: Analysis by Next Generation Sequencing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30146025" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Management of BK Polyomavirus Infection in Kidney and Kidney-Pancreas Transplant Recipients: A Review Article.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22711361" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Dynamics of pregnancy-associated polyomavirus urinary excretion: a prospective longitudinal study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30076973" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : BK polyomavirus in the urine for follow-up of kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29896858" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Prediction of BK viremia by urine viral load in renal transplant patients: An analysis of BK viral load results in paired urine and plasma samples.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27737395" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Screening for BK virus nephropathy in kidney transplant recipients: comparison of diagnostic tests.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29809315" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Clinical characteristics and outcomes of late-onset BK virus nephropathy in kidney and kidney-pancreas transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30297686" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Risk Factors of Acute Rejection in Patients with BK Nephropathy After Reduction of Immunosuppression.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29143415" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Severe BK polyomavirus-induced hemorrhagic cystitis in a kidney transplant recipient with the absence of renal allograft involvement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31054192" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Severe hemorrhagic cystitis caused by the BK polyomavirus is associated with decreased survival post-allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19505653" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : BK virus and human cancer: innocent until proven guilty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12131691" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Bladder carcinoma in a transplant recipient: evidence to implicate the BK human polyomavirus as a causal transforming agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28980390" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Treatment for presumed BK polyomavirus nephropathy and risk of urinary tract cancers among kidney transplant recipients in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21114642" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Reducing immunosuppression preserves allograft function in presumptive and definitive polyomavirus-associated nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19298172" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Monthly screening for polyoma virus eliminates BK nephropathy and preserves renal function.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30175491" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : New England BK consortium: Regional survey of BK screening and management protocols in comparison to published consensus guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25959495" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : BK virus screening and management practices among US renal transplant programs: a survey.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26590390" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Perception, diagnosis and management of BK polyomavirus replication and disease in paediatric kidney transplant recipients in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30859620" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : BK polyomavirus in solid organ transplantation-Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19845597" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : KDIGO clinical practice guideline for the care of kidney transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16771813" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : BK virus infection in transplant recipients: an overview and update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20353405" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Cost-efficient screening for BK virus in pediatric kidney transplantation: a single-center experience and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17908275" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Prospective monitoring of polyomavirus BK replication and impact of pre-emptive intervention in pediatric kidney recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23545506" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Screening for BK viremia reduces but does not eliminate the risk of BK nephropathy: a single-center retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18562587" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Marked variability of BK virus load measurement using quantitative real-time PCR among commonly used assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18562587" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Marked variability of BK virus load measurement using quantitative real-time PCR among commonly used assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31105020" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : The development and establishment of the 1st WHO BKV International Standard for nucleic acid based techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28053213" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Calibration of BK Virus Nucleic Acid Amplification Testing to the 1st WHO International Standard for BK Virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28100494" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Quantification of BK Virus Standards by Quantitative Real-Time PCR and Droplet Digital PCR Is Confounded by Multiple Virus Populations in the WHO BKV International Standard.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27668162" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : High-level viruria as a screening tool for BK virus nephropathy in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12138148" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Clinical course of polyoma virus nephropathy in 67 renal transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16734629" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Polyomavirus-associated nephropathy: update in diagnosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19394729" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Polyomavirus nephropathy: a current perspective and clinical considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15575913" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Histological patterns of polyomavirus nephropathy: correlation with graft outcome and viral load.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The American Society of Transplantation Infectious Diseases Guidelines</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9921805" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Human polyoma virus-associated interstitial nephritis in the allograft kidney.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10573064" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Diagnosis and management of BK polyomavirus interstitial nephritis in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29279304" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : The Banff Working Group Classification of Definitive Polyomavirus Nephropathy: Morphologic Definitions and Clinical Correlations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32654412" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : The 2018 Banff Working Group classification of definitive polyomavirus nephropathy: A multicenter validation study in the modern era.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30896679" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A Multicenter Application of the 2018 Banff Classification for BK Polyomavirus-associated Nephropathy in Renal Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28422412" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Histological Evolution of BK Virus-Associated Nephropathy: Importance of Integrating Clinical and Pathological Findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12694076" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Polyomavirus infection and acute vascular rejection in a kidney allograft: coincidence or mimicry?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20590692" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : A case of second renal transplantation with acute antibody-mediated rejection complicated with BK virus nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19734851" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : The significance of renal C4d staining in patients with BK viruria, viremia, and nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19158358" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Presence of urinary Haufen accurately predicts polyomavirus nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25136849" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Polyomavirus nephropathy: quantitative urinary polyomavirus-Haufen testing accurately predicts the degree of intrarenal viral disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25933251" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Polyomaviruses and disease: is there more to know than viremia and viruria?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27821629" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Polyomavirus Reactivation and Immune Responses to Kidney-Specific Self-Antigens in Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20090569" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Treatment of polyomavirus infection in kidney transplant recipients: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23018881" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Management and outcome of BK viremia in renal transplant recipients: a prospective single-center study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30476254" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Reducing calcineurin inhibitor first for treating BK polyomavirus replication after kidney transplantation: long-term outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25736704" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Commercially available immunoglobulins contain virus neutralizing antibodies against all major genotypes of polyomavirus BK.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16421486" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Intravenous immunoglobulin as a treatment for BK virus associated nephropathy: one-year follow-up of renal allograft recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28405598" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Clearance of BK Virus Nephropathy by Combination Antiviral Therapy With Intravenous Immunoglobulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18822106" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Intravenous immunoglobulin as rescue therapy for BK virus nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25769580" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Efficacy of intravenous immunoglobulin in the treatment of persistent BK viremia and BK virus nephropathy in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32741096" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Intravenous immunoglobulin as a preventive strategy against BK virus viremia and BKV-associated nephropathy in kidney transplant recipients-Results from a proof-of-concept study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16534472" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Treatment of renal allograft polyoma BK virus infection with leflunomide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16433758" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Concurrent antiviral and immunosuppressive activities of leflunomide in vivo.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22461534" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Leflunomide efficacy and pharmacodynamics for the treatment of BK viral infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17666021" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Leflunomide treatment for polyomavirus BK-associated nephropathy after kidney transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20811320" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Assessment of efficacy and safety of FK778 in comparison with standard care in renal transplant recipients with untreated BK nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10589927" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Cidofovir-induced end-stage renal failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12544881" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Quantitative viral load monitoring and cidofovir therapy for the management of BK virus-associated nephropathy in children and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12686681" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : BK transplant nephropathy successfully treated with cidofovir.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996251" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15996251" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Adjuvant low-dose cidofovir therapy for BK polyomavirus interstitial nephritis in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10709441" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : [Renal tolerance of cidofovir].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16734632" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Polyomavirus-associated nephropathy: update on antiviral strategies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15712075" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Ciprofloxacin decreased polyoma BK virus load in patients who underwent allogeneic hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16274519" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Urological manifestations of BK polyomavirus in renal transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17503741" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Inhibition of Simian virus 40 large T antigen helicase activity by fluoroquinolones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20507960" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Evaluation of fluoroquinolones for the prevention of BK viremia after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24482066" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Efficacy of levofloxacin in the treatment of BK viremia: a multicenter, double-blinded, randomized, placebo-controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25399012" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Levofloxacin for BK virus prophylaxis following kidney transplantation: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24482067" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Treatment of BK viremia after renal transplantation: are fluoroquinolones a false dawn?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18813104" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Antirejection treatment in kidney transplant patients with BK viruria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18360261" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Acute renal allograft rejection: diagnostic significance of focal peritubular capillary C4d.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18360267" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Successful treatment of BK viremia using reduction in immunosuppression without antiviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23016678" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Risk factors and interventional strategies for BK polyomavirus infection after renal transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21836535" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Results of repeat renal transplantation after graft loss from BK virus nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25910469" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Kidney retransplantation for BK virus nephropathy with active viremia without allograft nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11965053" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Successful retransplantation after renal allograft loss to polyoma virus interstitial nephritis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14520634" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Retransplantation after kidney graft loss due to polyoma BK virus nephropathy: successful outcome without original allograft nephrectomy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31765056" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Outcomes of kidney retransplantation after graft loss as a result of BK virus nephropathy in the era of newer immunosuppressant agents.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16433777" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Preemptive retransplantation for BK virus nephropathy: successful outcome despite active viremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14724448" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Retransplantation in patients with graft loss caused by polyoma virus nephropathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20353461" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Retransplantation after BK virus nephropathy in prior kidney transplant: an OPTN database analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
